Victoria Socha

DocwireNews

Patients with chronic kidney disease commonly experience gout, a clinical manifestation of inflammation in joints and soft tissue induced by hyperuricemia. Gout in patients with CKD may exacerbate declines in kidney function. Few data are available on monitoring of gout episodes and treatment practices among the CKD population, despite a growing burden globally.
During a poster session at ASN Kidney Week 2024, Deepika Laddu, PhD, and colleagues presented results of a multi-country study examining the prevalence, patient characteristics, and medical management of patients with gout and nondialysis-dependent moderate to advanced CKD. The poster was titled Gout Prevalence and Management Strategies Among Patients With Moderate to Advanced CKD.
The researchers analyzed cross-sectional data from the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDOPPS) on 942 enrolled patients in Brazil and 2,582 enrolled patients in the United States (total, 3,524). Eligible patients had nondialysis-dependent CKD stage 3b-5. Study coordinators extracted data on the history of gout (yes/no) from medical records. Patient characteristics, gout treatment, and uric acid measurement practices were summarized based on gout diagnosis and country.
Overall, the prevalence of gout was 19%. In the United States, the prevalence was 21%; in Brazil, the prevalence was 14%. In both countries, gout prevalence was higher in patients with CKD stage 4-5 compared to those with CKD stage 3b. Compared to patients without gout, those with gout were more likely to be male (66% vs 49%). Despite similar levels of body mass index across the groups, patients with gout had a higher prevalence of cardiovascular comorbidities.
In the group with gout, the most utilized gout treatment was allopurinol in both the United States and Brazil (62% and 75%, respectively). In the United States, colchicine and febuxostat were also used (13% and 8%, respectively); both were rarely used in Brazil (&lt;5%).
In the United States, mean uric acid among the patients with gout was 7.0 mg/dL in Brazil and 6.7 mg/dL in the United States. Only 30% of patients with gout in the United States had a uric acid measurement compared to 70% in Brazil.
In conclusion, the researchers said, “Gout affects a substantial proportion of the nondialysis CKD population, with differing management and monitoring strategies between the United States and Brazil. Further examination of the effectiveness of gout diagnosis and treatment practices between countries may provide an important opportunity to improve patient outcomes.”
Source: Laddu D, Sylvertooth D, Guedes MH, et al. Gout prevalence and management strategies among patients with moderate to advanced CKD. FR-PO1117. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2024; October 25, 2024; San Diego, California.

Patients with chronic kidney disease commonly experience gout, a clinical manifestation of inflammation in joints and soft tissue induced by hyperuricemia. Gout in patients with CKD may exacerbate declines in kidney function. Few data are available on monitoring of gout episodes and treatment practices among the CKD population, despite a growing burden globally.During a poster session at ASN Kidney Week 2024, Deepika Laddu, PhD, and colleagues presented results of a multi-country study examining the prevalence, patient characteristics, and medical management of patients with gout and nondialysis-dependent moderate to advanced CKD. The poster was titled Gout Prevalence and Management Strategies Among Patients With Moderate to Advanced CKD.The researchers analyzed cross-sectional data from the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDOPPS) on 942 enrolled patients in Brazil and 2,582 enrolled patients in the United States (total, 3,524). Eligible patients had nondialysis-dependent CKD stage 3b-5. Study coordinators extracted data on the history of gout (yes/no) from medical records. Patient characteristics, gout treatment, and uric acid measurement practices were summarized based on gout diagnosis and country.Overall, the prevalence of gout was 19%. In the United States, the prevalence was 21%; in Brazil, the prevalence was 14%. In both countries, gout prevalence was higher in patients with CKD stage 4-5 compared to those with CKD stage 3b. Compared to patients without gout, those with gout were more likely to be male (66% vs 49%). Despite similar levels of body mass index across the groups, patients with gout had a higher prevalence of cardiovascular comorbidities.In the group with gout, the most utilized gout treatment was allopurinol in both the United States and Brazil (62% and 75%, respectively). In the United States, colchicine and febuxostat were also used (13% and 8%, respectively); both were rarely used in Brazil (&lt;5%).In the United States, mean uric acid among the patients with gout was 7.0 mg/dL in Brazil and 6.7 mg/dL in the United States. Only 30% of patients with gout in the United States had a uric acid measurement compared to 70% in Brazil.In conclusion, the researchers said, “Gout affects a substantial proportion of the nondialysis CKD population, with differing management and monitoring strategies between the United States and Brazil. Further examination of the effectiveness of gout diagnosis and treatment practices between countries may provide an important opportunity to improve patient outcomes.”Source: Laddu D, Sylvertooth D, Guedes MH, et al. Gout prevalence and management strategies among patients with moderate to advanced CKD. FR-PO1117. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2024; October 25, 2024; San Diego, California.

Leslie Feldman

Can Leeches Spread Hepatitis B? New Research Says It's Unlikely

Hepatitis

Nsisong Asanga, PhD

New Study Shows Extended Mesenteric Resection Has No Benefits in Crohn’s Disease

Gastroenterology

New Discovery Reveals How the Body May Help Defeat Hepatitis B

Latest News

Managing Gout in Patients With Moderate to Advanced CKD

ASN Kidney Week 2024

A study examined the prevalence, patient characteristics, and medical management of patients with gout and nondialysis-dependent moderate to advanced chronic kidney disease (CKD).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe